Current HIV/AIDS Reports

, Volume 9, Issue 1, pp 44–51 | Cite as

Human Microbiome and HIV/AIDS

  • Deepak Saxena
  • Yihong Li
  • Liying Yang
  • Zhiheng Pei
  • Michael Poles
  • William R. Abrams
  • Daniel Malamud
The Science of HIV (AL Landay, Section Editor)

Abstract

Understanding of the human microbiome continues to grow rapidly; however, reports on changes in the microbiome after HIV infection are still limited. This review surveys the progress made in methodology associated with microbiome studies and highlights the remaining challenges to this field. Studies have shown that commensal oral, gut, vaginal, and penile bacteria are vital to the health of the human immune system. Our studies on crosstalk among oral and gastrointestinal soluble innate factors, HIV, and microbes indicated that the oral and gut microbiome was altered in the HIV-positive samples compared to the negative controls. The importance of understanding the bacterial component of HIV/AIDS, and likelihood of “crosstalk” between viral and bacterial pathogens, will help in understanding the role of the microbiome in HIV-infected individuals and facilitate identification of novel antiretroviral factors for use as novel diagnostics, microbicides, or therapeutics against HIV infection.

Keywords

HIV Oral microbiome Oral manifestation Innate immunity 454 pyrosequencing Gut microbiome Highly Active Antiretroviral Therapy Crosstalk 

Notes

Acknowledgments

The study was supported by the National Institute of Dental and Craniofacial Research (NIDCR) grants U19-DE018385, RO3-DE019178, RO1-DE020891, and UH3CA140233 from Human Microbiome Project of the National Institutes of Health Roadmap Initiative and National Cancer Institute. We acknowledge the advice and support of our Program Directors at NIDCR for U19-DE018385: Dr. Lillian Shum and Dr. Isaac R. Rodriguez-Chavez.

Disclosure

No potential conflicts of interest relevant to this article were reported.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Brenchley JM, Price DA, Schacker TW, et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med. 2006;12:1365–71.PubMedCrossRefGoogle Scholar
  2. 2.
    Kanwar B, Favre D, McCune JM. Th17 and regulatory T cells: implications for AIDS pathogenesis. Curr Opin HIV AIDS. 2010;5:151–7.PubMedCrossRefGoogle Scholar
  3. 3.
    Fiocchi C. One commensal bacterial molecule. All we need for health? N Engl J Med. 2005;353:2078–80.PubMedCrossRefGoogle Scholar
  4. 4.
    MacDonald TT, Monteleone G. Immunity, inflammation, and allergy in the gut. Science. 2005;307:1920–5.PubMedCrossRefGoogle Scholar
  5. 5.
    •• MacDonald TT, Monteleone I, Fantini MC, et al. Regulation of homeostasis and inflammation in the intestine. Gastroenterology. 2011;140:1768–75. Explains some aspects of gut immunity that could alter the delicate balance between inflammatory and tolerogenic responses and result in chronic gastrointestinal tract inflammation in patients.PubMedCrossRefGoogle Scholar
  6. 6.
    Gill SR, Pop M, Deboy RT, et al. Metagenomic analysis of the human distal gut microbiome. Science. 2006;312:1355–9.PubMedCrossRefGoogle Scholar
  7. 7.
    Kau AL, Ahern PP, Griffin NW, et al. Human nutrition, the gut microbiome and the immune system. Nature. 2011;474:327–36.PubMedCrossRefGoogle Scholar
  8. 8.
    Ley RE, Knight R, Gordon JI. The human microbiome: eliminating the biomedical/environmental dichotomy in microbial ecology. Environ Microbiol. 2007;9:3–4.PubMedCrossRefGoogle Scholar
  9. 9.
    Ley RE, Peterson DA, Gordon JI. Ecological and evolutionary forces shaping microbial diversity in the human intestine. Cell. 2006;124:837–48.PubMedCrossRefGoogle Scholar
  10. 10.
    Turnbaugh PJ, Gordon JI. The core gut microbiome, energy balance and obesity. J Physiol. 2009;587:4153–8.PubMedCrossRefGoogle Scholar
  11. 11.
    Turnbaugh PJ, Gordon JI. An invitation to the marriage of metagenomics and metabolomics. Cell. 2008;134:708–13.PubMedCrossRefGoogle Scholar
  12. 12.
    Turnbaugh PJ, Ley RE, Hamady M, et al. The human microbiome project. Nature. 2007;449:804–10.PubMedCrossRefGoogle Scholar
  13. 13.
    Peterson J, Garges S, Giovanni M, et al. The NIH human microbiome project. Genome Res. 2009;19:2317–23.PubMedCrossRefGoogle Scholar
  14. 14.
    Lederberg J. Infectious history. Science. 2011;288:287–93.CrossRefGoogle Scholar
  15. 15.
    Anderson M, Bollinger D, Hagler A, et al. Viable but nonculturable bacteria are present in mouse and human urine specimens. J Clin Microbiol. 2004;42:753–8.PubMedCrossRefGoogle Scholar
  16. 16.
    Dehio C. Bartonella-host-cell interactions and vascular tumour formation. Nat Rev Microbiol. 2005;3:621–31.PubMedCrossRefGoogle Scholar
  17. 17.
    Fenollar F, Raoult D. Molecular diagnosis of bloodstream infections caused by non-cultivable bacteria. Int J Antimicrob Agents. 30, Supplement 2007, 1:7–15.Google Scholar
  18. 18.
    Ji X, Pushalkar S, Li Y, et al. Antibiotic effects on bacterial profile in osteonecrosis of the jaw. Oral Dis. 2011. doi: 10.1111/j.1601-0825.2011.01848.
  19. 19.
    Li Y, Ge Y, Saxena D, et al. Genetic profiling of the oral microbiota associated with severe early-childhood caries. J Clin Microbiol. 2007;45:81–7.PubMedCrossRefGoogle Scholar
  20. 20.
    Li Y, Ku CY, Xu J, et al. Survey of oral microbial diversity using PCR-based denaturing gradient gel electrophoresis. J Dent Res. 2005;84:559–64.PubMedCrossRefGoogle Scholar
  21. 21.
    Pushalkar S, Mane SP, Ji X, et al. Microbial diversity in saliva of oral squamous cell carcinoma. FEMS Immunol Med Microbiol. 2011;61:269–77.PubMedCrossRefGoogle Scholar
  22. 22.
    Ahn J, Yang L, Paster BJ, et al. Oral microbiome profiles: 16S rRNA pyrosequencing and microarray assay comparison. PLoS One. 2011;6:e22788.PubMedCrossRefGoogle Scholar
  23. 23.
    Sogin ML, Morrison HG, Huber JA, et al. Microbial diversity in the deep sea and the underexplored “rare biosphere”. Proc Natl Acad Sci. 2006;103:12115–20.PubMedCrossRefGoogle Scholar
  24. 24.
    Stoeck T, Behnke A, Christen R, et al. Massively parallel tag sequencing reveals the complexity of anaerobic marine protistan communities. BMC Biol. 2009;7:72.PubMedCrossRefGoogle Scholar
  25. 25.
    •• Hamady M, Knight R. Microbial community profiling for human microbiome projects: tools, techniques, and challenges. Genome Res. 2009;19:1141–52. The paper addresses the challenges in high-throughput sequencing and also addresses one key question emerging from various Human Microbiome Projects: Is there a substantial core of abundant organisms or lineages that we all share? PubMedCrossRefGoogle Scholar
  26. 26.
    Ledergerber C, Dessimoz C. Base-calling for next-generation sequencing platforms. Brief Bioinform. 2011. doi: 10.1093/bib/bbq077.
  27. 27.
    Nossa CW, Oberdorf WE, Yang L, et al. Design of 16S rRNA gene primers for 454 pyrosequencing of the human foregut microbiome. World J Gastroenterol. 2010;16:4135–44.PubMedCrossRefGoogle Scholar
  28. 28.
    Wommack KE, Bhavsar J, Ravel J. Metagenomics: read length matters. Appl Environ Microbiol. 2008;74:1453–63.PubMedCrossRefGoogle Scholar
  29. 29.
    Caporaso JG, Kuczynski J, Stombaugh J, et al. QIIME allows analysis of high-throughput community sequencing data. Nat Meth. 2010;7:335–6.CrossRefGoogle Scholar
  30. 30.
    DeSantis TZ, Hugenholtz P, Larsen N, et al. Greengenes, a chimera-checked 16S rRNA gene database and workbench compatible with ARB. Appl Environ Microbiol. 2006;72:5069–72.PubMedCrossRefGoogle Scholar
  31. 31.
    Huson DH, Auch AF, Qi J, et al. MEGAN analysis of metagenomic data. Genome Res. 2007;17:377–86.PubMedCrossRefGoogle Scholar
  32. 32.
    Haas BJ, Gevers D, Earl AM, et al. Chimeric 16S rRNA sequence formation and detection in Sanger and 454-pyrosequenced PCR amplicons. Genome Res. 2011;21:494–504.PubMedCrossRefGoogle Scholar
  33. 33.
    Clayton RA, Sutton G, Hinkle PS, et al. Intraspecific variation in small-subunit rRNA sequences in GenBank: why single sequences may not adequately represent prokaryotic taxa. Int J Syst Bacteriol. 1995;45:595–9.PubMedCrossRefGoogle Scholar
  34. 34.
    Janda JM, Abbott SL. 16S rRNA gene sequencing for bacterial identification in the diagnostic laboratory: pluses, perils, and pitfalls. J Clin Microbiol. 2007;45:2761–4.PubMedCrossRefGoogle Scholar
  35. 35.
    Ashelford KE, Chuzhanova NA, Fry JC, et al. At least 1 in 20 16S rRNA sequence records currently held in public repositories is estimated to contain substantial anomalies. Appl Environ Microbiol. 2005;71:7724–36.PubMedCrossRefGoogle Scholar
  36. 36.
    Cole JR, Wang Q, Cardenas E, et al. The ribosomal database project: improved alignments and new tools for rRNA analysis. Nucleic Acids Res. 2009;37:D141–5.PubMedCrossRefGoogle Scholar
  37. 37.
    Chen T, Yu W-H, Izard J, et al. The human oral microbiome database: a web accessible resource for investigating oral microbe taxonomic and genomic information. Database. 2010:baq013. doi: 10.1093/database/baq013
  38. 38.
    • Dewhirst FE, Chen T, Izard J, et al. The human oral microbiome. J Bacteriol. 2010;192:5002–17. The human oral cavity contains a number of different habitats, including the teeth, gingival sulcus, tongue, cheeks, hard and soft palates, and tonsils, which are colonized by bacteria. The oral microbiome is comprised of over 600 prevalent taxa at the species level, with distinct subsets predominating at different habitats. The HOMD is the first curated description of a human-associated microbiome and provides tools for use in understanding the role of the microbiome in health and disease. PubMedCrossRefGoogle Scholar
  39. 39.
    Griffen AL, Beall CJ, Firestone ND, et al. CORE: a phylogenetically-curated 16S rDNA database of the core oral microbiome. PLoS One. 2011;6:e19051.PubMedCrossRefGoogle Scholar
  40. 40.
    Greenspan D, Canchola AJ, MacPhail LA, et al. Effect of highly active antiretroviral therapy on frequency of oral warts. Lancet. 2001;357:1411–2.PubMedCrossRefGoogle Scholar
  41. 41.
    Greenspan D, Gange SJ, Phelan JA, et al. Incidence of oral lesions in HIV-1-infected women: reduction with HAART. J Dent Res. 2004;83:145–50.PubMedCrossRefGoogle Scholar
  42. 42.
    Greenspan JS, Barr CE, Sciubba JJ, et al. Oral manifestations of HIV infection: definitions, diagnostic criteria and principles of therapy. Oral Med Oral Pathol Oral Radiol. 1992;73:142–4.Google Scholar
  43. 43.
    Hamza O, Matee M, Simon E, et al. Oral manifestations of HIV infection in children and adults receiving highly active anti-retroviral therapy [HAART] in Dar es Salaam, Tanzania. BMC Oral Health. 2006;6:12.PubMedCrossRefGoogle Scholar
  44. 44.
    Ceballos-Salobreña A, Gaitán-Cepeda LA, Ceballos-Garcia L, et al. Oral lesions in HIV/AIDS patients undergoing highly active antiretroviral treatment including protease inhibitors: a new face of oral AIDS? AIDS Patient Care STDs. 2000;14:627–35.PubMedCrossRefGoogle Scholar
  45. 45.
    Mulligan R, Seirawan H, Alves ME, et al. Oral health-related quality of life among HIV-infected and at-risk women. Community Dent Oral Epidemiol. 2008;36:549–57.PubMedCrossRefGoogle Scholar
  46. 46.
    Navazesh M, Mulligan R, Pogoda J, et al. The effect of HAART on salivary microbiota in the Women’s Interagency HIV study (WIHS). Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2005;100:701–8.PubMedCrossRefGoogle Scholar
  47. 47.
    Phelan JA, Mulligan R, Nelson E, et al. Dental caries in HIV-seropositive women. J Dent Res. 2004;83:869–73.PubMedCrossRefGoogle Scholar
  48. 48.
    Shiboski CH, Patton LL, Webster-Cyriaque JY, et al. The oral HIV/AIDS research alliance: updated case definitions of oral disease endpoints. J Oral Pathol Med. 2009;38:481–8.PubMedCrossRefGoogle Scholar
  49. 49.
    •• Shiboski CH, Webster-Cyriaque JY, Ghannoum M, et al. Overview of the oral HIV/AIDS research alliance program. Adv Dent Res. 2011;23:28–33. The Oral HIV/AIDS Research Alliance is part of the AIDS Clinical Trials Group, the largest HIV clinical trial organization in the world, and it is funded by the National Institute of Dental and Craniofacial Research, in collaboration with the National Institute of Allergy and Infectious Diseases. The alliance’s main objective is to investigate the oral complications associated with HIV/AIDS as the epidemic is evolving—in particular, the effects of potent antiretrovirals on the development of oral mucosal lesions and associated fungal and viral pathogens. PubMedCrossRefGoogle Scholar
  50. 50.
    Auvert B, Taljaard D, Lagarde E, et al. Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 trial. PLoS Med. 2005;2:e298.PubMedCrossRefGoogle Scholar
  51. 51.
    Bailey RC, Moses S, Parker CB, et al. Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial. Lancet. 2007;369:643–56.PubMedCrossRefGoogle Scholar
  52. 52.
    Gray RH, Kigozi G, Serwadda D, et al. Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial. Lancet. 2007;369:657–66.PubMedCrossRefGoogle Scholar
  53. 53.
    •• Price LB, Liu CM, Johnson KE, et al. The effects of circumcision on the penis microbiome. PLoS ONE. 2010;5:e8422. The reduction in putative anaerobic bacteria after circumcision may play a role in protection from HIV and other sexually transmitted diseases. PubMedCrossRefGoogle Scholar
  54. 54.
    •• Tobian AAR, Serwadda D, Quinn TC, et al. Male circumcision for the prevention of HSV-2 and HPV infections and syphilis. N Engl J Med. 2009;360:1298–309. Male circumcision for the prevention of herpes simplex virus type 2 and human papillomavirus infections and syphilis in HIV-negative adolescent boys and men. PubMedCrossRefGoogle Scholar
  55. 55.
    Wawer MJ, Tobian AAR, Kigozi G. Effect of circumcision of HIV-negative men on transmission of human papillomavirus to HIV-negative women: a randomised trial in Rakai, Uganda. Lancet. 2011;377:209–18.PubMedCrossRefGoogle Scholar
  56. 56.
    Anderson D, Politch JA, Pudney J. HIV infection and immune defense of the penis. Am J Reprod Immunol. 2011;65:220–9.PubMedCrossRefGoogle Scholar
  57. 57.
    Lamont RF, Sobel JD, Akins RA, et al. The vaginal microbiome: new information about genital tract flora using molecular based techniques. BJOG. 2011;118:533–49.PubMedCrossRefGoogle Scholar
  58. 58.
    •• White BA, Creedon DJ, Nelson KE. The vaginal microbiome in health and disease. Trends Endocrinol Metabol. 2011;389–93. Authors discussed how next-generation sequencing-based approaches to study the vaginal microbiome will be important for defining what constitutes an imbalance of the microbiome and the associated host conditions that lead to subsequent infection and disease states. Google Scholar
  59. 59.
    Spear GT, Gilbert D, Sikaroodi M, et al. Identification of rhesus macaque genital microbiota by 16S pyrosequencing shows similarities to human bacterial vaginosis: implications for use as an animal model for HIV vaginal infection. AIDS Res Hum Retrovir. 2010;26:193–200.PubMedCrossRefGoogle Scholar
  60. 60.
    • Hummelen R, Fernandes AD, Macklaim JM, et al. Deep sequencing of the vaginal microbiota of women with HIV. PLoS One. 2010;5:e12078. Illumina-based 16S sequencing technique was used to determine vaginal microbiota among women living with HIV in sub-Saharan Africa. The bacterial profile constitutes several bacteria associated with a normal microbiota or BV. PubMedCrossRefGoogle Scholar
  61. 61.
    •• McMahon JM, Morrow KM, Weeks M, et al. Potential impact of vaginal microbicides on HIV risk among women with primary heterosexual partners. J Assoc Nurses AIDS Care. 2011;22:9–16. Universal promotion of microbicides could nonetheless lead to an increase in HIV risk among specific subgroups of women, indicating the importance of promoting continued condom use. PubMedCrossRefGoogle Scholar
  62. 62.
    • Ravel J, Gajer P, Abdo Z, et al. Vaginal microbiome of reproductive-age women. Proc Natl Acad Sci U S A. 108 Suppl 2011, 1:4680–7. The inherent differences within and between women in different ethnic groups strongly argue for a more refined definition of the kinds of bacterial communities normally found in healthy women and the need to appreciate differences between individuals so they can be taken into account in risk assessment and disease diagnosis. Google Scholar
  63. 63.
    Spear GT, Gilbert D, Landay AL, et al. Pyrosequencing of the genital microbiotas of HIV-seropositive and -seronegative women reveals lactobacillus iners as the predominant lactobacillus species. Appl Environ Microbiol. 2010;77:378–81.PubMedCrossRefGoogle Scholar
  64. 64.
    Jousimies-Somer H. Recently described clinically important anaerobic bacteria: taxonomic aspects and update. Clin Infect Dis. 25 Suppl 1997, 2:S78–87.Google Scholar
  65. 65.
    Peng L, He Z, Chen W, et al. Effects of butyrate on intestinal barrier function in a Caco-2 cell monolayer model of intestinal barrier. Pediatr Res. 2007;2007(61):37–41.CrossRefGoogle Scholar
  66. 66.
    Wikoff WR, Anfora AT, Liu J. Metabolomics analysis reveals large effects of gut microflora on mammalian blood metabolites. Proc Natl Acad Sci U S A. 2009;106:3698–703.PubMedCrossRefGoogle Scholar
  67. 67.
    Hummelen R, Vos AP, van't Land B, et al. Altered host-microbe interaction in HIV: a target for intervention with pro- and prebiotics. Int Rev Immunol. 2010;29:485–513.PubMedCrossRefGoogle Scholar
  68. 68.
    Mehandru S, Poles MA, Tenner-Racz K, et al. Mechanisms of gastrointestinal CD4+ T-cell depletion during acute and early human immunodeficiency virus type 1 infection. J Virol. 2007;81:599–612.PubMedCrossRefGoogle Scholar
  69. 69.
    Haas A, Zimmermann K, Graw F, et al. Systemic antibody responses to gut commensal bacteria during chronic HIV-1 infection. Gut. 2011;60:1506–19.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  • Deepak Saxena
    • 1
  • Yihong Li
    • 1
  • Liying Yang
    • 2
  • Zhiheng Pei
    • 2
  • Michael Poles
    • 3
  • William R. Abrams
    • 1
  • Daniel Malamud
    • 1
  1. 1.Department of Basic Science and Craniofacial BiologyNew York University College of DentistryNew YorkUSA
  2. 2.Department of PathologyNew York University Langone Medical CenterNew YorkUSA
  3. 3.Departments of MedicineNew York University Langone Medical CenterNew YorkUSA

Personalised recommendations